Author: OurCrowd

[Stellar Cyber in BusinessWire] Stellar Cyber’s Jim O’Hara and Andrew Homer named to 2025 CRN® Channel Chiefs List

Feb 3, 2025 |

SAN JOSE, Calif.–(BUSINESS WIRE)–Stellar Cyber Chief Revenue Officer Jim O’Hara and VP of Strategic Alliances Andrew Homer both have been named to the prestigious 2025 CRN® Channel Chiefs list. CRN produces the Channel Chiefs list to showcase the top leaders throughout the IT channel ecosystem who work tirelessly with their partners and customers to ensure mutual success. The list recognizes IT vendor and distribution executives who drive strategy and set the channel agenda for their companies and the industry. Read more...

Read More

[Alpha Tau in Alpha Tau] Alpha Tau announces FDA approval of IDE supplement to expand pilot trial of Alpha DaRT® to thirty patients with pancreatic cancer in two cohorts, with locally advanced or metastatic disease

Feb 3, 2025 |

JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients. Read...

Read More